Companies › Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd (TAK): Financial Statements and Key Figures
Takeda Pharmaceutical Co Ltd (ticker TAK) is classified by the SEC under industry code 2834, Pharmaceutical Preparations, and is listed on NYSE. It files its annual report with the U.S. Securities and Exchange Commission (SEC) on Form 20-F and reports in JPY. Its fiscal 2025 ended on 31 March 2025; the annual report for that year was filed on 25 June 2025. For that year it reported revenue of JPY 4,581,551 million, net income of JPY 107,928 million and total assets of JPY 14,248,344 million at the year end. Fiscal years 2018 to 2025 are shown below.
The figures are as the company filed them, standardised by reporting tag; the filing is the authority. For education and analysis, not investment advice.
Key Figures
Money in JPY millions; earnings per share in JPY. Free cash flow is the cash from operating activities less capital expenditures. Total debt is short-term plus long-term debt, or the total the company itself tags when that is larger. A margin is the profit line divided by revenue; return on equity is net income divided by the average of shareholders' equity at the start and the end of the year. A blank cell means the company does not report the line under a standard tag; it does not mean zero.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| year ended on | 31 Mar | 31 Mar | 31 Mar | 31 Mar | 31 Mar | 31 Mar | 31 Mar | 31 Mar |
| Revenue (JPY millions) | 1,770,531 | 2,097,224 | 3,291,188 | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,551 |
| Net income (JPY millions) | 186,886 | 135,192 | 44,241 | 376,005 | 230,059 | 317,017 | 144,067 | 107,928 |
| Earnings per share, diluted (JPY) | 237.56 | 139.82 | 28.25 | 238.96 | 145.87 | 201.94 | 91.16 | 67.23 |
| Cash from operating activities (JPY millions) | 377,854 | 328,479 | 669,752 | 1,010,931 | 1,123,105 | 977,156 | 716,344 | 1,057,182 |
| Free cash flow (JPY millions) | 310,849 | 250,802 | 542,670 | 899,725 | 999,853 | 836,499 | 540,924 | 856,387 |
| Total assets (JPY millions) | 4,106,463 | 13,792,773 | 12,821,094 | 12,912,293 | 13,178,018 | 13,957,750 | 15,108,792 | 14,248,344 |
| Total debt (JPY millions) | 985,662 | 5,750,951 | 5,093,304 | 4,635,371 | 4,345,411 | 4,382,341 | 4,843,752 | 4,515,265 |
| Shareholders' equity (JPY millions) | 1,997,424 | 5,181,985 | 4,723,483 | 5,173,037 | 5,683,019 | 6,354,122 | 7,273,264 | 6,935,084 |
| Gross margin | 72.0 % | 68.9 % | 66.9 % | 68.9 % | 69.0 % | 69.1 % | 66.5 % | 65.5 % |
| Operating margin | 13.7 % | 11.3 % | 3.1 % | 15.9 % | 12.9 % | 12.2 % | 5.0 % | 7.5 % |
| Net margin | 10.6 % | 6.4 % | 1.3 % | 11.8 % | 6.4 % | 7.9 % | 3.4 % | 2.4 % |
| Return on equity | 9.4 % | 3.8 % | 0.9 % | 7.6 % | 4.2 % | 5.3 % | 2.1 % | 1.5 % |
Last twelve months: not shown. No quarterly reports in XBRL (the company files annual, half-year or current reports only): no last-twelve-month figures, none estimated.
Charts
Figure 1: Revenue and net income by fiscal year (JPY millions)
Figure 2: Cash from operating activities and free cash flow by fiscal year (JPY millions)
Compound Growth
The compound annual growth rate is the single yearly rate that, applied every year, takes the first value to the last one: the last value divided by the first, raised to the power of one over the number of years, less one. It uses only the two end values, so an unusual first or last year moves it a great deal.
- Revenue: 1,770,531 in fiscal 2018 to 4,581,551 in fiscal 2025 (JPY millions), 7 years: 14.5 % a year.
- Diluted earnings per share: 237.56 in fiscal 2018 to 67.23 in fiscal 2025 (JPY per share), 7 years: −16.5 % a year.
Analyse This Company
Each link opens a calculator with Takeda Pharmaceutical Co Ltd loaded from the same data.
- Company Financial Statements: The full income statement, balance sheet and cash flow statement of each fiscal year, with common-size and growth views.
- Capital Allocation History: Where the cash from operations went each year: capital expenditures, dividends, share repurchases, debt.
- Dividend Sustainability: How the dividends paid compare with earnings and with free cash flow, year by year.
- Earnings Quality Trend: How much of reported earnings arrived as cash, and how accruals moved over the years.
- Reverse DCF: The growth in free cash flow that a share price you type would assume.
- Financial Quality Scores: The Piotroski F-score and the DuPont breakdown of return on equity, worked step by step.
- Valuation Range: What a share price you type corresponds to as multiples of earnings, cash flow and book value, against the company's own history.
Several companies at once: Peer Comparison and Fundamental Screener.
Same Industry
The first 12 in alphabetical order of the 24 other companies in the data with the industry code 2834 (Pharmaceutical Preparations), in alphabetical order; the index lists every company.
- Abbott Laboratories (ABT)
- AbbVie Inc. (ABBV)
- Alnylam Pharmaceuticals, Inc. (ALNY)
- Astrazeneca plc (AZN)
- BeOne Medicines Ltd. (ONC)
- Bristol Myers Squibb Co (BMY)
- ELI LILLY & Co (LLY)
- Genmab A/s (GMAB)
- GSK plc (GSK)
- INSMED Inc (INSM)
- Johnson & Johnson (JNJ)
- Merck & Co., Inc. (MRK)
Source
The annual report first filed for each fiscal year, with a link to its index page on EDGAR, the SEC's filing system. A later annual report repeats earlier years for comparison and sometimes restates them; where a value was taken from a later report, the last column gives the date of the latest one used.
| Fiscal year | Year ended | Form | Filed | On EDGAR | Later report used, filed |
|---|---|---|---|---|---|
| 2025 | 31 Mar 2025 | Form 20-F | 25 Jun 2025 | filing index | |
| 2024 | 31 Mar 2024 | Form 20-F | 26 Jun 2024 | filing index | 25 Jun 2025 |
| 2023 | 31 Mar 2023 | Form 20-F | 28 Jun 2023 | filing index | 25 Jun 2025 |
| 2022 | 31 Mar 2022 | Form 20-F | 29 Jun 2022 | filing index | 26 Jun 2024 |
| 2021 | 31 Mar 2021 | Form 20-F | 29 Jun 2021 | filing index | 28 Jun 2023 |
| 2020 | 31 Mar 2020 | Form 20-F | 24 Jun 2020 | filing index | 29 Jun 2022 |
| 2019 | 31 Mar 2019 | Form 20-F | 27 Jun 2019 | filing index | 29 Jun 2021 |
| 2018 | 31 Mar 2018 | Form 20-F | 27 Jun 2019 | filing index | 24 Jun 2020 |
- The figures are as filed with the SEC and standardised by reporting tag. The filing is the authority: check it before relying on a number.
- A blank cell means the company does not tag that line, or the tagged figure is withheld as incomplete. It does not mean zero.
- Currency: every figure is in the currency the company reported that year (JPY here). Nothing is converted.
- Per-share figures are adjusted for stock splits detected from the company's own restated figures, except where a year is flagged; the as-filed values are in the filings.
- For a bank, broker, insurer or other financial company (SIC codes 6000 to 6799) net debt, EBITDA, the current ratio and debt to equity are not meaningful and the tools show them as n/m.
- A fiscal year is named after the calendar year in which it ends. The data is updated from time to time, not daily; this company's figures were loaded on 13 November 2026.
For education and analysis, not investment advice.